Cullinan Therapeutics, Inc. (CGEM) Stock

Cullinan Therapeutics, Inc. (CGEM) is a Healthcare stock trading at $15.06 (as of 2026-06-18), with a market capitalization of $1.01B and a trailing P/E of -4.0. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, zipalertinib (CLN-081/TAS6417), CLN-049, and CLN-617.

Valuation — source: SEC EDGAR (first-party)
Price	$15.06
Market Cap	$1.01B
P/E Ratio	-4.0
EV / EBITDA	-3.4
Price / Book	2.42
Price / Sales	44.98
DCF Value (model)	$-47.99
DCF Upside vs Price	-418.7%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$22.21M
Net Margin	-989.9%
Return on Equity	-60.4%
Current Ratio	10.28
Revenue Growth (YoY)	-25.1%
FCF Growth (YoY)	21.0%

Financial Health — source: SEC EDGAR
Altman Z-Score	11.16 (safe)

Valuation vs Sector & Industry
Stock P/E	-4.0
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-119.2%
vs Industry	-123.6%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	Lynx1 Capital Management LP ($127.37M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Nadim Ahmed
Employees	111
Country	US
IPO Date	2021-01-08

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.